Back to Search
Start Over
Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV.
- Source :
- Vaccines; Mar2020, Vol. 8 Issue 1, p142, 1p
- Publication Year :
- 2020
-
Abstract
- Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169<superscript>+</superscript> macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169<superscript>+</superscript> macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre<superscript>+/ki</superscript> x Usp18<superscript>fl/fl</superscript> mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169<superscript>+</superscript> macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also. [ABSTRACT FROM AUTHOR]
- Subjects :
- IMMUNE response
MACROPHAGES
VACCINATION
EBOLA virus
BIOMARKERS
BACTERIAL vaccines
Subjects
Details
- Language :
- English
- ISSN :
- 2076393X
- Volume :
- 8
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 142496571
- Full Text :
- https://doi.org/10.3390/vaccines8010142